Table 1. Patient characteristics in the PCR array set.
| Patients with no recurrence (n=16) | Patients with recurrence (n=16) | P | |
|---|---|---|---|
| Mean age at diagnosis (min, max) | 54 (30 - 79) | 57 (43 - 75) | 0.624 |
| Menopausal status | |||
| Premenopausal | 6 (38%) | 3 (19) | |
| Postmenopausal | 10 (62%) | 13 (81) | 0.433 |
| Tumor size (cm) | |||
| Median ± SD | 2.6 ± 0.9 | 2.3 ± 2.1 | 0.615 |
| Nodal status | |||
| Negative | 8 (50%) | 4 (25%) | |
| Positive | 8 (50%) | 12 (75%) | 0.273 |
| Clinical T | |||
| T1 | 5 (31%) | 5 (31%) | |
| T2 | 9 (56%) | 8 (50%) | |
| T3 | 2 (13%) | 0 (0%) | |
| T4 | 0 (0%) | 3 (19%) | 0.168 |
| Stage | |||
| 1 | 1 (6%) | 4 (25%) | |
| 2 | 13 (81%) | 9 (56%) | |
| 3 | 2 (13%) | 3 (19%) | 0.256 |
| Nuclear grade | |||
| 1,2 | 9 (56%) | 10 (63%) | |
| 3 | 7 (44%) | 6 (38%) | 1.000 |
| Ki67 labeling index, median ± SD | 49 ± 21.3 | 36 ± 26.2 | 0.396 |
| ER status | |||
| Negative | 6 (38%) | 7 (44%) | |
| Positive (≥1%) | 10 (62%) | 9 (56%) | 1.000 |
| PR status | |||
| Negative | 8 (50%) | 8 (50%) | |
| Positive (≥1%) | 8 (50%) | 8 (50%) | 1.000 |
| Tumor subtype | |||
| Luminal (ER and/or PR + and HER2 -) | 9 (56%) | 9 (56%) | |
| HER2 (ER and/or PR +/- and HER2 +) | 4 (25%) | 4 (25%) | |
| TN (ER and PR and HER2 -) | 3 (19%) | 3 (19%) | 1.000 |
| Adjuvant treatment | |||
| Endocrine therapy | 11 (69%) | 9 (56%) | |
| Chemotherapy | 7 (44%) | 8 (50%) | |
| Trastuzumab | 2 (13%) | 3 (19%) |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2; SD, standard deviation; TN, triple negative.